Which psychotropic medications are most likely to interact with antiretroviral medications, and what are the common drug‑drug interactions?

Psychotropic-Antiretroviral Drug Interactions

The psychotropic medications most likely to interact with antiretrovirals are those metabolized through the cytochrome P450 system—particularly benzodiazepines (midazolam, triazolam, alprazolam), antipsychotics (quetiapine, lurasidone, pimozide), and certain antidepressants (tricyclics, some SSRIs)—with protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) posing the highest interaction risk through CYP3A4 inhibition or induction 1.

High-Risk Psychotropic Classes and Mechanisms

Benzodiazepines

• Contraindicated combinations: Midazolam, triazolam, and alprazolam with ritonavir-boosted PIs cause dangerous sedation and respiratory depression through CYP3A4 inhibition 1
• Safer alternatives: Lorazepam, oxazepam, and temazepam undergo glucuronidation rather than CYP metabolism and have no significant interactions with antiretrovirals 1

Antipsychotics

• High-risk agents: Quetiapine, lurasidone, and pimozide levels increase dramatically with PI use, risking QTc prolongation and torsades de pointes 1
• Moderate-risk agents: Risperidone, aripiprazole, and olanzapine require dose reductions (typically 25-50%) when combined with ritonavir-boosted PIs 1
• Additional concern: Both antiretrovirals and antipsychotics independently increase metabolic syndrome risk; combined use amplifies this effect 2

Antidepressants

• SSRIs: Generally safer profile, though paroxetine and fluoxetine (CYP2D6 inhibitors) may increase levels of certain antiretrovirals 1
• Tricyclics: Require dose reductions with PIs due to CYP2D6/3A4 metabolism; monitor for anticholinergic toxicity and cardiac conduction abnormalities 1
• Bupropion: Levels decrease significantly with efavirenz (CYP2B6 inducer), potentially reducing antidepressant efficacy 1

Antiretroviral Classes by Interaction Potential

Highest Risk: Protease Inhibitors (especially ritonavir-boosted)

• Mechanism: Potent CYP3A4 inhibition increases psychotropic drug levels 2-20 fold 1
• Clinical impact: Risk of severe sedation, respiratory depression, QTc prolongation, and serotonin syndrome
• Management: Avoid contraindicated combinations; reduce psychotropic doses by 50-75% when interactions are unavoidable

High Risk: NNRTIs

• Efavirenz: Strong CYP3A4 and CYP2B6 inducer, decreases levels of many psychotropics including bupropion, sertraline, and benzodiazepines 1
• Etravirine, nevirapine: Similar induction effects but less pronounced than efavirenz
• Clinical impact: Loss of psychotropic efficacy requiring dose increases

Minimal Risk: Integrase Inhibitors

• Raltegravir, dolutegravir, bictegravir: Not metabolized through CYP450, minimal interaction potential 3
• Preferred option: When psychotropic co-administration is necessary, integrase-based regimens minimize drug-drug interaction concerns

Minimal Risk: NRTIs

• All agents (tenofovir, emtricitabine, lamivudine, abacavir): Not CYP450 substrates, no dose adjustments needed with psychotropics 4

Common Specific Interactions

Opioid Use Disorder Medications

• Methadone + efavirenz: Methadone levels decrease 50-60%, causing withdrawal; increase methadone dose by 20-30% 1
• Buprenorphine + PIs: Buprenorphine levels increase but rarely requires dose adjustment; monitor for sedation 1
• Key point: Medications for substance use disorders have few clinically significant interactions and should not be withheld 5

Stimulants (ADHD treatment)

• Amphetamines + ritonavir: Potential for increased cardiovascular effects through CYP2D6 inhibition 1
• Methylphenidate: Minimal interaction potential as it's not significantly metabolized by CYP450 1

Mood Stabilizers

• Carbamazepine, phenobarbital, phenytoin: Strong CYP3A4 inducers that decrease antiretroviral levels, potentially causing virologic failure—avoid these combinations 6
• Valproic acid, lamotrigine: Minimal CYP involvement, safer alternatives for mood stabilization 1

Pharmacodynamic Interactions (Overlapping Toxicities)

Beyond metabolism-based interactions, watch for additive effects:

• QTc prolongation: Antipsychotics + efavirenz or rilpivirine increase arrhythmia risk 1
• CNS depression: Benzodiazepines + efavirenz (which causes CNS side effects) amplify sedation and dizziness 1
• Metabolic syndrome: PIs + atypical antipsychotics synergistically increase diabetes and dyslipidemia risk 2

Clinical Management Algorithm

Step 1: Identify the antiretroviral class

• If integrase inhibitor or NRTI-only regimen → proceed with standard psychotropic dosing
• If PI-based → anticipate need for psychotropic dose reduction
• If NNRTI-based → anticipate need for psychotropic dose increase

Step 2: Select psychotropics with lowest interaction potential

• Benzodiazepines: Use lorazepam, oxazepam, or temazepam
• Antidepressants: Prefer citalopram, escitalopram, or sertraline over paroxetine or tricyclics
• Antipsychotics: Avoid quetiapine, lurasidone, and pimozide with PIs

Step 3: Monitor for specific toxicities

• Baseline and follow-up ECGs when combining QTc-prolonging agents
• Metabolic panels every 3 months with PI + antipsychotic combinations
• Therapeutic drug monitoring for tricyclics when used with PIs

Step 4: Adjust doses preemptively

• With ritonavir-boosted PIs: Start psychotropics at 25-50% of standard dose
• With efavirenz: Consider 25-50% dose increases for psychotropics metabolized by CYP3A4

Critical Pitfalls to Avoid

1. Never assume newer antiretrovirals are interaction-free: While integrase inhibitors have minimal CYP involvement, cobicistat (a pharmacokinetic booster) behaves like ritonavir and causes similar interactions 1

2. Don't overlook pharmacodynamic interactions: Even when pharmacokinetic interactions are minimal, additive CNS depression or QTc effects remain clinically significant 1

3. Avoid automatic contraindication of substance use disorder medications: Despite theoretical concerns, methadone, buprenorphine, and naltrexone can be safely co-administered with antiretrovirals with appropriate monitoring 5

4. Don't delay psychiatric treatment: The morbidity and mortality impact of untreated depression and psychosis in HIV-infected patients outweighs interaction risks when managed appropriately 7, 1

5. Remember bidirectional interactions: Some psychotropics (particularly paroxetine and fluoxetine) inhibit CYP2D6 and may increase levels of certain antiretrovirals, though this is rarely clinically significant 1